# A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

> **NCT02069041** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 8 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **BIOLOGICAL:** Ramucirumab
- **DRUG:** FOLFOX4

## Key facts

- **NCT ID:** NCT02069041
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02069041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02069041, "A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02069041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*